Evidence map›Paper›PMID 26770167›Full record

ArticleIntegrative medicine (Encinitas, Calif.)2015

Nutritional Approach for Relief of Joint Discomfort: A 12-week, Open-case Series and Illustrative Case Report.

Robert H Lerman, Jyh-Lurn Chang, Veera Konda, Anuradha Desai, Michael B Montalto

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Integrative medicine (Encinitas, Calif.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Systems Biology Meets Functional Medicine.Integrative medicine (Encinitas, Calif.) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Robert H Lermanis the former director of medicine and extramural clinical research; is the manager for medical affairs; is the director of nutrition research; is the therapeutic platform lead for foundational health; and is the senior director of medical affairs. All are located at Metagenics, Inc, in Gig Harbor, Washington.
Jyh-Lurn Changis the former director of medicine and extramural clinical research; is the manager for medical affairs; is the director of nutrition research; is the therapeutic platform lead for foundational health; and is the senior director of medical affairs. All are located at Metagenics, Inc, in Gig Harbor, Washington.
Veera Kondais the former director of medicine and extramural clinical research; is the manager for medical affairs; is the director of nutrition research; is the therapeutic platform lead for foundational health; and is the senior director of medical affairs. All are located at Metagenics, Inc, in Gig Harbor, Washington.
Anuradha Desaiis the former director of medicine and extramural clinical research; is the manager for medical affairs; is the director of nutrition research; is the therapeutic platform lead for foundational health; and is the senior director of medical affairs. All are located at Metagenics, Inc, in Gig Harbor, Washington.
Michael B Montaltois the former director of medicine and extramural clinical research; is the manager for medical affairs; is the director of nutrition research; is the therapeutic platform lead for foundational health; and is the senior director of medical affairs. All are located at Metagenics, Inc, in Gig Harbor, Washington.
Iskra Medical (Slovenia) · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextTetrahydro iso-α acids (THIAAs), derived from Humulus lupulus (hops), have demonstrated anti-inflammatory effects in vitro and in an animal model of rheumatoid arthritis (RA). Undenatured type 2 collagen has been found to be effective in clinical studies in RA and osteoarthritis (OA).

objectiveThe study intended to evaluate the efficacy and safety of a proprietary tablet containing 150 mg of n-enriched THIAA (nTHIAA) and 10 mg of undenatured type 2 collagen (UC-II) (containing 25% UC-II) in patients with arthritis.

designThe study was an open-label case series. This article also includes a case history for 1 participant.

settingThe study was conducted at the Functional Medicine Research Center (FMRC) in Gig Harbor, WA, USA, from February 2013-June 2013.

participantsParticipants were 17 adults, 12 women, and 5 men aged 39-69 y, who had chronic joint pain involving various joints, 13 with probable OA and 4 with possible RA.

interventionParticipants took 2 tablets of nTHIAA + UC-II 2 ×/d with meals for 12 wk. OUTCOME MEASURES: Participants completed arthritis-related and quality-of-life questionnaires, at weeks 2, 4, 8, and 12: (1) the visual analog scale for pain (VAS-P); (2) the medical symptoms questionnaire (MSQ), with the analysis particularly focusing on the joint/muscle subscale and total scores; (3) the health and wellness outcome questionnaire (MOS-SF36), with the analysis particularly focusing on the physical and mental subscales; (4) the arthritis impact questionnaire (AIQ), with the analysis particularly focusing on the arthritis symptoms and daily living subscales; (5) the health assessment questionnaire (HAQ-DI) with the analysis particularly focusing on question 26 (Q26), which indicates overall pain during the week prior to the survey; and (6) the arthritis impact measurement scales 2 (AIMS2). At 12 wk, participants also completed the visual analog scale for efficacy (VAS-E).

resultsAll participants completed the 12-wk evaluation, and all reported improvements in pain. Significant improvements in scores on the questionnaires were observed as early as 2 wk. For example, the total score on the MSQ was significantly decreased from a mean of 20.76 ± 2.90 (SE) at baseline to 12.24 ± 2.81 after 2 wk (P < .001). At 12 wk, the participants rated the supplement's efficacy at 7.6 ± 0.6 of 10. At baseline, 13 of the 17 participants were using analgesics for joint pain, compared with only 4 participants at 12 wk. Two of those 4 had reduced their analgesic dosages. The studied supplement was well tolerated, and no serious side effects occurred.

conclusionsThe supplement containing nTHIAA and UC-II is safe and efficacious in participants with chronic joint pain.

Identifiers

PMID26770167
PMCPMC4712866
OpenAlexW2412163362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.